INSIGHTS ON SOLID DOSE MANUFACTURING

• The Future Of Oral Solid Dose Development And Innovation

  Tom Sellig, CEO of Adare, discusses the ongoing relevance of small molecules, oral solid dose development, trends like GLP-1, and innovations like 3D printing in pharmaceuticals.

• Advances In Oral GLP-1 Analogs For Obesity

  Discover how these groundbreaking Oral GLP-1 Analogs therapies are reshaping obesity management and addressing key challenges in formulation and delivery.

• Fundamentals Of Power Blending Simulations

  Predicting blending quality doesn't have to be a guessing game. Learn how to leverage virtual prototypes to make informed decisions and minimize costly trial-and-error in tablet manufacturing.

• Orally-Disintegrating Dosage Forms With Taste Masked Multiparticulates

  Learn more about our orally disintegrating tablet (ODT) capabilities and how these innovative technologies have the potential to improve acceptance, adherence, and compliance in pharmacotherapy.

• How To Avoid Sticking And Picking In The Tableting Industry

  9/23/2024

  Review strategies to mitigate sticking and picking risks in the tablet industry, and learn how you can foster improved tablet production processes, ensuring higher quality and consistency.

• The Importance Of Polymorph Screenings

  5/6/2026

  Discover how systematic polymorph screening reduces development risk, safeguards product performance, and enables confident solid‑form selection across the drug development lifecycle.

• Bottling Solutions

  3/4/2025

  Explore a bottling solution that is meticulously engineered to adhere to the most stringent pharmaceutical standards, which guarantees that each product is crafted with unparalleled quality and precision.

• Tablets And Capsules: Overcoming Similar Obstacles In Production

  7/30/2024

  Explore how understanding specific USP chapters can address common tablet and capsule production challenges and ensure high-quality results in this essential pharmaceutical process.

• Closing The Duration Gap In FDA-Approved Long-Acting Contraceptives

  7/17/2024

  A gap exists between three months and three years in FDA-approved long-acting contraceptives (LACs). A microsphere formulation enables sustained release over a six to twelve-month period.